Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery

A method of increasing HSP70 levels in ocular tissue comprising administering topically on the ocular surface an effective amount of a GGA derivative.

A pharmaceutical composition suitable for parenteral administration to a patient, wherein the pharmaceutical composition comprises a GGA derivative and at least one excipient for introducing the GGA derivative into the eye of a subject.

A physiological supplement or medicament for ophthalmic use, in the form of eye drops, comprising a GGA derivative in a range of about 0.0005%-20%.

A formulation for treatment of an ocular neural disease, disorder or condition, comprising a GGA derivative, and at least one carrier material for introducing a GGA derivative into the eye of a subject suffering from the neural disease, disorder or condition.

A method of treating glaucoma, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a GGA derivative.

A method of inhibiting apoptosis of a retinal ganglion cell, the method comprising administration a pharmaceutical formulation of a GGA derivative to the cell.

An eye drop for the treatment of an ocular neural disease, disorder or condition through topical application of said eye drop to the eye of a subject suffering from said disease, disorder or condition, comprising a therapeutically effective amount of a GGA derivative.

A method of delivering a GGA derivative into a retina of a subject, the method comprising ocular administration to the subject of the GGA derivative.

A method of treating a retinal disease in a subject, the method comprising administering topically on an ocular surface of the subject an effective amount of a GGA derivative.

A method of inhibiting a retinal optical nerve damage in a subject, the method comprising ocular administration to the subject of an effective amount of a GGA derivative.